Novavax Inc (NVAX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Financial ... [Yahoo! Finance]
Novavax, Inc. (NVAX)
Last novavax, inc. earnings: 3/11 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.novavax.com/investor-relations
Company Research
Source: Yahoo! Finance
Licensing, Royalties, and Other Revenue: $492 million for 2024. 4th Quarter Revenue: $88 million, with $50 million from product sales. R&D and SG&A Expenses: Reduced by 40% in 2024 compared to 2023. 4th Quarter R&D and SG&A Expenses: $183 million, a 43% reduction from the same period in 2023. Cash and Receivables: Over $1 billion at the end of 2024. Sale of Czech Republic Facility: $200 million, contributing to a $52 million gain in Q4. Current Liabilities Reduction: Decreased by $481 million in 2024. 2025 Revenue Framework: Expected adjusted licensing, royalties, and other revenue between $300 million and $350 million. 2025 R&D and SG&A Expense Target: Between $475 million and $525 million, with a focus on R&D. Milestone Payments: Potential $225 million from COVID-19 BLA approval and market authorization transfers. Warning! GuruFocus has detected 4 Warning Signs with NVAX. Release Date: February 27, 2025 For the complete transcript of the earnings call, pleas
Show less
Read more
Impact Snapshot
Event Time:
NVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVAX alerts
High impacting Novavax, Inc. news events
Weekly update
A roundup of the hottest topics
NVAX
News
- New Report Urges Action to Ensure Sustainable, Affordable Supply of Key Vaccine Adjuvants for Global Health Use [Yahoo! Finance]Yahoo! Finance
- Why I Wouldn't Touch Novavax With a 10-Foot Pole [Yahoo! Finance]Yahoo! Finance
- Novavax (NASDAQ:NVAX) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Novavax, Inc. (NVAX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Pharma Stocks Fall After Leaked Memo Questions Vaccine Safety [Barron's]Barrons
NVAX
Earnings
- 11/6/25 - Miss
NVAX
Sec Filings
- 11/12/25 - Form SCHEDULE
- 11/6/25 - Form 8-K
- 11/6/25 - Form 10-Q
- NVAX's page on the SEC website